ALDX Earnings & Financial Statements
Aldeyra Therapeutics, Inc.
$0.78
-$0.01(-1.71%)
28
Overall
50
Value
18
Tech
18
Quality
Market Cap
$47.68M
Volume
657.95K
52W Range
$0.86 - $5.93
Target Price
$6.25
ALDX earnings and financial statements: Aldeyra Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ALDX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$35.27M | -$60.12M | -$42.79M | -$62.68M | -$56.22M |
| EBITDA | -$31.42M | -$53.55M | -$36.88M | -$60.07M | -$55.77M |
| Net income | -$33.80M | -$55.90M | -$37.50M | -$62.02M | -$57.78M |
| EPS (diluted) | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $72.06M | $104.61M | $148.33M | $181.29M | $233.14M |
| Total liabilities | $27.81M | $33.60M | $28.53M | $30.28M | $27.40M |
| Shareholders’ equity | $44.25M | $71.00M | $119.80M | $151.01M | $205.74M |
| Cash and equivalents | - | - | - | $144.42M | $125.00M |
| Long-term debt | - | $15.00M | $271.6K | $14.92M | $15.63M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$33.35M | -$43.21M | -$30.33M | -$56.64M | -$42.56M |
| Capital expenditure | - | - | - | -$16.3K | -$7.8K |
| Free cash flow | -$33.35M | -$43.21M | -$30.33M | -$56.65M | -$42.56M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALDX | $0.78 | -1.7% | 657.95K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aldeyra Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW